- Product Pipeline Review - H2 2011” provides a detailed overview on the Inovio Pharmaceuticals, Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Inovio Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Inovio Pharmaceuticals, Inc. and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- Inovio Pharmaceuticals, Inc. - Brief Inovio Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Inovio Pharmaceuticals, Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Inovio Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Inovio Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Inovio Pharmaceuticals, Inc.’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of Inovio Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Inovio Pharmaceuticals, Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Inovio Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Inovio Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Biopharmaceutical Industry in the United States
Table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 9
Inovio Pharmaceuticals, Inc. Snapshot 10
Inovio Pharmaceuticals, Inc. Overview 10
Key Information 10
Key Facts 10
Inovio Pharmaceuticals, Inc. – Research and Development Overview 11
Key Therapeutic Areas 11
Inovio Pharmaceuticals, Inc. – Pipeline Review 14
Pipeline Products by Stage of Development 14
Inovio Pharmaceuticals, Inc. – Pipeline Products Glance 15
Inovio Pharmaceuticals, Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Inovio Pharmaceuticals, Inc.–Early Stage Pipeline Products 17
Pre-Clinical Products/Combination Treatment Modalities 17
Inovio Pharmaceuticals, Inc. – Drug Profiles 18
ChronVac C 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
INO-3401 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
INO-3510 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
INO-3605 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
INO-3605 + INO-3609 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
INO-3609 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INO-5150 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Malaria DNA Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PENNVAX-B DNA Vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PENNVAX-G 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PENNVAX-GP 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PSMA Vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SynCon Chikungunya Virus DNA Vaccine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VGX-1027 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VGX-3100 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VGX-3400X 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Inovio Pharmaceuticals, Inc. – Pipeline Analysis 42
Inovio Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 42
Inovio Pharmaceuticals, Inc. - Pipeline Products By Target 44
Inovio Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 46
Inovio Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 47
Inovio Pharmaceuticals, Inc. – Recent Pipeline Updates 48
Inovio Pharmaceuticals, Inc. - Dormant Projects 51
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
Pictoir 52
PICTOVIR 52
Inovio Pharmaceuticals, Inc. – Firms Statement 53
Inovio Pharmaceuticals, Inc. – Operations and Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
October 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 57
August 31, 2006: VGX Pharmaceuticals Announces The Initiation Of IND-enabling Toxicology Studies For VGX-150 57
November 30, 2009: Tripep completes Phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine 58
September 30, 2010: Inovio's SynCon Universal Influenza DNA Vaccine Technology Recognized With NIH Director's Transformative Research Award 58
June 30, 2009: Inovio Biomedical, National Microbiology Laboratory, And University Of Pennsylvania To Evaluate Candidate DNA Vaccines Against "Swine" Influenza A (H1N1) 59
May 30, 2007: Tripep Receives Patent Protection For Administration Of ChronVac-C Vaccine Using Electroporation 60
December 29, 2005: VGX Pharmaceuticals Announces Preliminary Results on the Phase I/II Clinical Trials of PICTOVIR 60
September 29, 2008: VGX Pharmaceuticals Commences Follow-On Phase I Study For November el Oral Anti-Inflammatory Drug 61
July 29, 2009: Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies 61
July 29, 2009: Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies 62
September 28, 2010: Inovio' HIV DNA Vaccine/Electroporation Delivery Technology Gets Selected For NIH-Sponsored US Army Human Clinical Trial 63
April 28, 2010: ChronTech Pharma Releases Positive Results From ChronVac-C-study 64
November 27, 2007: The First Patient With Chronic Hepatitis C Initiates Treatment with Tripep’s ChronVac-C Vaccine 64
October 26, 2005: Inovio Initiates Clinical Trial Using its Selective Electrochemical Tumor Ablation Therapy In Recurrent Breast Cancer 65
March 26, 2009: VGX Pharmaceuticals Announces Phase I Study Results Of VGX-1027 66
June 25, 2008: VGX Announces Publication Of Preclinical Data For The Firms ’s Avian flu Vaccine Candidate In PLoS ONE Journal 66
February 23, 2009: VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered With Electroporation Provides 100% Protection Of Non-Human Primates 67
May 22, 2007: Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency Of Gene-Based Prostate Cancer Vaccine 68
September 21, 2010: Inovio Completes Enrollment Of HIV Clinical Trial For DNA Vaccine Delivered Using Electroporation 68
August 21, 2005: VGX Pharmaceuticals Announces FDA Acceptance of IND Application For VGX-410C 69
November 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 69
November 20, 2009: Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses In Pre-Clinical Studies 70
November 20, 2008: Hepatitis C Therapeutic DNA Vaccine Delivered By Inovio Biomedical's Electroporation Technology Reduces Viral Load By Up To 99.7% 71
October 19, 2009: Phase I Clinical Study Of PENNVAX-B Preventive DNA Vaccine Using Electroporation Technology 71
June 19, 2007: Inovio Biomedical's Selective Electrochemical Tumor Ablation Therapy Shows Safety, Tolerability, And Significant Complete Responses In Breast Cancer Study 72
May 19, 2008: VGX Pharmaceuticals Announces Filing Of INDs Covering November el DNA Vaccine For Avian Influenza (VGX-3400) 72
May 19, 2008: VGX Pharmaceuticals Announces Filings Of INDs Covering November el DNA Vaccine For The Cervical Cancer Therapy (VGX-3100) 73
November 18, 2009: Inovio Biomedical Universal DNA Vaccine For Chikungunya Virus Demonstrates Protective Antibody Responses In Monkey Model 74
July 18, 2005: Vical Begins Phase 1 Trial Of Gene-Based IL-2 With Inovio Electroporation Technology 74
February 18, 2009: VGX Pharmaceuticals Proprietary DNA Vaccines Delivered With Electroporation Achieve Immune Responses Superior To Recombinant Adenovirus Serotype 5 (Ad5) Vectors 75
February 18, 2009: VGX Pharmaceuticals Proprietary DNA Vaccines Delivered with Electroporation Achieves Immune Responses Superior To Recombinant Adenovirus Serotype 5 (Ad5) Vectors 76
February 18, 2009: VGX Pharmaceuticals Provides Clinical Update On PENNVAX HIV Vaccines Programs 76
November 17, 2010: Inovio Pharmaceuticals' HIV DNA Vaccine Achieves Strong T-Cell Immune Responses In Phase I Human Trial 77
July 17, 2006: VGX Pharmaceuticals Provides Update on Additional Phase II Clinical Trial for PICTOVIR 78
August 16, 2007: Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of November el Vaccine for Hepatitis C Virus 79
July 16, 2008: Inovio Biomedical's First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu In Pre-Clinical Testing 79
January 16, 2006: Tripep Initiates Clinical Development Of ChronVac-C For The Treatment Of Chronic Hepatitis C Virus Infection In Collaboration With US Firms Inovio 80
October 15, 2008: VGX Pharmaceuticals Presents Non-human Primate Study Data At AIDS Vaccine 2008 Conference 81
September 15, 2010: Inovio Receives Follow-On Funding From PATH Malaria Vaccine Initiative For DNA Vaccine Development 82
August 15, 2007: Tripep Receives Approval To Start A Phase I/II Study Of The ChronVac-C Vaccine As A Treatment For Chronic Infections By The Hepatitis C Virus 83
July 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 83
June 15, 2010: Inovio Immunizes First Subject In US Influenza DNA Vaccine Clinical Trial 84
November 14, 2006: Inovio Biomedical Grants VGX Pharmaceuticals License to Develop November el Cancer Therapeutic VGX 150 85
September 14, 2011: Inovio Completes PENNVAX-B HIV Vaccine Phase I Study 86
July 14, 2011: Inovio Demonstrates Positive Immune Responses In Phase I Clinical Trial of SynCon H5N1 Influenza Vaccine 87
July 14, 2011: Inovio Launches Multi-Subtype Influenza Vaccine Phase I Trial 88
March 14, 2011: Inovio's Partner ChronTech Initiates Phase II Clinical Trial Of HCV DNA Vaccine 89
January 14, 2008: VGX Pharmaceuticals Receives FDA Clearance To Commence Clinical Trials Of VGX-1027 89
December 13, 2007: VGX Pharmaceuticals Announces The Discontinuation Of VGX-410C Development And The Concentration Of Its Efforts On HIV And Other Product Pipelines 90
October 13, 2006: VGX Pharmaceuticals Completes Manufacturing of New Oncology Drug VGX-150 For Phase I Clinical Trials 91
September 13, 2010: Inovio Achieves Unprecedented T-Cell Immune Responses In Human Trial Of DNA Vaccine For Cervical Dysplasia And Cancer Caused By HPV 91
February 13, 2009: VGX Pharmaceuticals Announces Filing Of Device Master File Amendment with the FDA for CELLECTRA Device – Intradermal Electroporation (ID-EP) 93
February 13, 2009: VGX Pharmaceuticals Announces Filing Of Device Master File Amendment With The FDA For CELLECTRA Device Used In Delivering VGX-3100 94
November 12, 2010: Inovio Pharmaceuticals To Present HIV Study Update At HVTN Conference 94
November 12, 2007: VGX Pharmaceuticals' SynCon Pandemic Flu Vaccine (VGX-3400) Protects Against A Lethal Challenge Of Live Virus In Pre-Clinical Animal Models 95
March 12, 2009: Tripep Receives Approval Of ChronVac-C From Swedish Medical Products Agency 95
January 12, 2011: Inovio Announces Publication Of Preclinical Results Of Chikungunya DNA Vaccine In PLoS Neglected Tropical Diseases 96
September 11, 2006: VGX Pharmaceuticals Announces Publication Of Preclinical Animal Efficacy Studies For VGX-150 In Molecular Therapy 97
August 10, 2009: Inovio Biomedical And NIH Vaccine Research Center Sign Research Collaboration Agreement To Develop Universal Influenza Vaccines 97
January 10, 2011: Inovio Announces Positive Preclinical Results From DNA Vaccine For Clade C HIV 98
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 99
March 09, 2006: VGX Pharmaceuticals Announces IND Submission For Additional Phase II Clinical Trials for PICTOVIR 100
April 08, 2010: Inovio Completes Enrollment Of Cervical Cancer Therapeutic Vaccine Study 100
February 08, 2010: Inovio Biomedical Announces Additional Interim Safety And Immunogenicity Data Of VGX-3100 Against Cervical Cancer 102
February 08, 2008: VGX Pharmaceuticals Announces The IND Filing Of VGX-3200 103
December 07, 2010: Inovio Announces Publication Of Preclinical Efficacy Results Of Smallpox DNA Vaccine In The Journal Of Infectious Diseases 103
July 07, 2008: VGX Pharmaceuticals Announces The Discontinuation of Its PICTOVIR Program 104
June 07, 2007: Vical Interim Clinical Results for Interleukin-2 to Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation Dna Delivery Technology 105
March 07, 2011: Inovio Pharmaceuticals Enters Phase II Clinical Trial With SynCon DNA Vaccine For Cervical Dysplasia Caused by HPV 105
October 05, 2009: Inovio Biomedical Demonstrates Protective Immune Responses Against November el H1N1 (2009) Influenza Virus In Ferret Model 106
October 05, 2009: Inovio Biomedical Demonstrates Protective Immune Responses Against November el H1N1 (2009) Influenza Virus In Ferret Model 107
October 05, 2009: Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety And Immunogenicity In Clinical Trial 107
June 05, 2008: Inovio Biomedical Provides Updated Interim Data On Phase I/II Clinical Study Of Electroporation-Delivered Prostate Cancer DNA Vaccine 109
June 05, 2007: Inovio Biomedical Stops Enrollment Of Phase III Clinical Trials For Head & Neck Cancer 109
June 04, 2008: Tripep Reports Positive Results From Its Ongoing ChronVac-C Study 110
April 04, 2005: Inovio Biomedical Initiates A Phase I/II Clinical Trial In Patients With Recurrent Prostate Cancer 111
September 02, 2007: VGX Pharmaceuticals Announces The Completion Of Patient Enrollment For The Firms ’s Phase II Trial for VGX-410C 111
June 02, 2009: Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential To Protect Against Newly Emerging Flu Strains With Pandemic Potential 112
June 02, 2009: Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential To Protect Against Newly Emerging Flu Strains With Pandemic Potential 113
March 02, 2010: Inovio Receives Korean Approval To Begin Clinical Trials Of H5N1 Avian Influenza DNA Vaccine 114
February 02, 2011: Inovio's Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial 114
December 01, 2004: VGX Pharmaceuticals Announces FDA Acceptance of IND Application For PICTOVIR (formally known as VGX-410) 115
November 01, 2004: VGX Pharmaceuticals Announces IND Submission for PICTOVIR 115
July 01, 2008: VGX Pharmaceuticals Receives FDA Approval Of IND For November el DNA Vaccine For Cervical Cancer Therapy 116
February 01, 2007: Inovio Presents MedPulser Electrochemical Tumor Ablation Results At 5th International Symposium On Advances In Head & Neck Cancer 116
Financial Deals Landscape 118
Inovio Pharmaceuticals, Inc., Merger and Acquisition Deal Summary 118
Inovio Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 121
Asset Transactions 121
Inovio Biomedical Takes Over DNA Delivery And Expression Assets From Valentis 121
Genetronics Takes Over Technologies From Valentis 123
Venture Financing 124
VGX Pharmaceuticals Secures US$ 4 Mln In Venture Financing 124
VGX Pharmaceuticals Secures US$ 0.5 Mln In Seed Round Of Financing 125
Partnerships 126
Inovio Biomedical Concludes a New Deal With Cardigant Medical 126
Inovio Biomedical Expands Licensing Agreement With International AIDS Vaccine Initiative 127
Genetronics Biomedical Concludes a new deal With Vical 128
Inovio Biomedical Enters Into Research Agreement With Vaccine Research Center 129
Tripep Enters Into Agreement With Inovio 130
Genetronics Enters Into Co-Development Agreement With National Cancer Institute 131
Inovio Biomedical Concludes a new deal With Tripep 132
Genetronics Concludes a New Deal With RMR Technologies 133
Merger 134
Inovio Biomedical Merges With VGX Pharmaceuticals 134
Licensing Agreements 136
Inovio Pharmaceuticals Expands Licensing Agreement With University Of Pennsylvania 136
Inovio Pharmaceuticals Enters Into Licensing Agreement With OncoSec Medical 137
Inovio Biomedical Expands Licensing Agreement With University Of Pennsylvania 138
VGX Pharmaceuticals Expands Licensing Agreement With University of Pennsylvania 139
Inovio Biomedical Concludes a new deal With Advanced BioScience Laboratories 140
Inovio Biomedical Enters Into Licensing Agreement With University Of Pennsylvania 141
VGX Pharmaceuticals Enters Into Licensing Agreement With Baylor College of Medicine 142
Dowpharma Concludes a New Deal With VGX Pharmaceuticals 143
VGX Pharmaceuticals Enters Into Licensing Agreement With University of Pennsylvania 144
Inovio Biomedical Concludes a new deal With VGX Pharmaceuticals 145
Inovio Biomedical Concludes a new deal With Wyeth Pharmaceuticals 146
Inovio Biomedical Enters Into Agreement With RMR Technologies 147
Inovio Biomedical Enters Into Licensing Agreement With Sphergen 148
VGX Pharmaceuticals Enters Into In-Licensing Agreement With Ganial Immunotherapeutics 149
Merck & Co. Expands Licenisng Agreement With Inovio Biomedical 150
Genetronics Biomedical Enters Into Licensing Agreement With Merck 151
Equity Offering 152
Inovio Pharmaceuticals Files Registration Statement For A Public Offering Of Securities For US$ 75 Mln 152
Inovio Pharmaceuticals Completes Private Placement Of US$ 3.8 Mln 154
Inovio Pharmaceuticals Completes An Underwritten Registered Offering For US$ 24 Mln 156
Inovio Biomedical Completes Registered Direct Offering Of US$ 30 Mln 158
Inovio Biomedical Completes Private Placement Of US$ 16.17 Mln 160
Inovio Completes Private Placement Of US$ 9.9 Mln 162
Inovio Asia Completes Private Placement Of US$ 5.35 Mln 164
Inovio Biomedical Completes Private Placement Of US$ 15.8 Mln 166
Genetronics Biomedical Completes Private Placement Of US$ 6.24 Mln 168
Genetronics Biomedical Completes Private Placement Of US$ 10.9 Mln 170
Acquisition 172
Genetronics Takes Over Inovio 172
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 174
Contact Us 174
Disclaimer 174
List of Tables
Inovio Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 13
Inovio Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 14
Inovio Pharmaceuticals, Inc. - Phase II, H2 2011 15
Inovio Pharmaceuticals, Inc. - Phase I, H2 2011 16
Inovio Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011 43
Inovio Pharmaceuticals, Inc. - Pipeline By Target, H2 2011 45
Inovio Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011 46
Inovio Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011 47
Inovio Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011 48
Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010 51
Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010 52
Inovio Pharmaceuticals, Inc., Subsidiaries 56
Inovio Pharmaceuticals, Inc., Merger and Acquisition Deal Summary 118
Inovio Biomedical Takes Over DNA Delivery And Expression Assets From Valentis 121
Genetronics Takes Over Technologies From Valentis 123
VGX Pharmaceuticals Secures US$ 4 Mln In Venture Financing 124
VGX Pharmaceuticals Secures US$ 0.5 Mln In Seed Round Of Financing 125
Inovio Biomedical Concludes a New Deal With Cardigant Medical 126
Inovio Biomedical Expands Licensing Agreement With International AIDS Vaccine Initiative 127
Genetronics Biomedical Concludes a new deal With Vical 128
Inovio Biomedical Enters Into Research Agreement With Vaccine Research Center 129
Tripep Enters Into Agreement With Inovio 130
Genetronics Enters Into Co-Development Agreement With National Cancer Institute 131
Inovio Biomedical Concludes a new deal With Tripep 132
Genetronics Concludes a New Deal With RMR Technologies 133
Inovio Biomedical Merges With VGX Pharmaceuticals 134
Inovio Pharmaceuticals Expands Licensing Agreement With University Of Pennsylvania 136
Inovio Pharmaceuticals Enters Into Licensing Agreement With OncoSec Medical 137
Inovio Biomedical Expands Licensing Agreement With University Of Pennsylvania 138
VGX Pharmaceuticals Expands Licensing Agreement With University of Pennsylvania 139
Inovio Biomedical Concludes a new deal With Advanced BioScience Laboratories 140
Inovio Biomedical Enters Into Licensing Agreement With University Of Pennsylvania 141
VGX Pharmaceuticals Enters Into Licensing Agreement With Baylor College of Medicine 142
Dowpharma Concludes a New Deal With VGX Pharmaceuticals 143
VGX Pharmaceuticals Enters Into Licensing Agreement With University of Pennsylvania 144
Inovio Biomedical Concludes a new deal With VGX Pharmaceuticals 145
Inovio Biomedical Concludes a new deal With Wyeth Pharmaceuticals 146
Inovio Biomedical Enters Into Agreement With RMR Technologies 147
Inovio Biomedical Enters Into Licensing Agreement With Sphergen 148
VGX Pharmaceuticals Enters Into In-Licensing Agreement With Ganial Immunotherapeutics 149
Merck & Co. Expands Licenisng Agreement With Inovio Biomedical 150
Genetronics Biomedical Enters Into Licensing Agreement With Merck 151
Inovio Pharmaceuticals Files Registration Statement For A Public Offering Of Securities For US$ 75 Mln 152
Inovio Pharmaceuticals Completes Private Placement Of US$ 3.8 Mln 154
Inovio Pharmaceuticals Completes An Underwritten Registered Offering For US$ 24 Mln 156
Inovio Biomedical Completes Registered Direct Offering Of US$ 30 Mln 158
Inovio Biomedical Completes Private Placement Of US$ 16.17 Mln 160
Inovio Completes Private Placement Of US$ 9.9 Mln 162
Inovio Asia Completes Private Placement Of US$ 5.35 Mln 164
Inovio Biomedical Completes Private Placement Of US$ 15.8 Mln 166
Genetronics Biomedical Completes Private Placement Of US$ 6.24 Mln 168
Genetronics Biomedical Completes Private Placement Of US$ 10.9 Mln 170
Genetronics Takes Over Inovio 172
List of Figures
Inovio Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011 12
Inovio Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011 14
Inovio Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011 42
Inovio Pharmaceuticals, Inc. - Pipeline By Target, H2 2011 44
Inovio Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011 46
Inovio Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011 47
